A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Crizotinib (Primary) ; Sorafenib (Primary) ; Vemurafenib (Primary)
- Indications Cancer; Cancer metastases
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 17 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018, as reported by ClinicalTrials.gov.